A receptor-by-receptor breakdown of how single, dual, and triple agonists act on GLP-1, GIP, and glucagon. What each receptor controls, which effects (and side effects) trace back to which arm, and what trials measure to capture them.
GLP-1, GIP, and glucagon receptors each control distinct physiology. GLP-1R agonism drives central appetite suppression, delayed gastric emptying (transient, with tachyphylaxis), and glucose-dependent insulin secretion — and is the source of most class-typical nausea and GI tolerability signals. GIPR agonism adds glucose-dependent insulinotropic amplification, modulates adipocyte fed/fasted handling, and appears to attenuate GLP-1-driven nausea in translational data. GcgR agonism adds hepatic glucose output (offset clinically by the GLP-1 arm), increases resting energy expenditure, mobilizes hepatic triglyceride, and carries a modest resting heart rate signal. Trial outcomes from semaglutide, tirzepatide, and retatrutide map cleanly to these receptor profiles.
This page is a receptor-first explainer for researchers comparing agonist classes. For drug-specific data, see the retatrutide profile (GLP-1 / GIP / glucagon), semaglutide profile (GLP-1 only), or survodutide profile (GLP-1 / glucagon). For research-use only.
Receptor
Receptor
Receptor
The GLP-1 receptor is expressed in the hypothalamic arcuate nucleus, the brainstem area postrema and nucleus of the solitary tract (NTS), pancreatic β-cells, the cardiovascular system, and the gastrointestinal tract. Central activation drives POMC/CART-mediated appetite suppression and engages the area-postrema circuits implicated in nausea and vomiting [1,5]. Pancreatic GLP-1R activation amplifies insulin secretion in a glucose-dependent manner, which limits hypoglycaemia risk as monotherapy [3].
Acute gastric-emptying delay is substantial in early dosing but undergoes rapid tachyphylaxis at the vagal level; with long-acting agonists (12 weeks or more) emptying largely normalises [2]. This matters for trial endpoint interpretation — gastric-emptying-driven satiety dominates the first month, central appetite suppression dominates after.
Trial weight outcomes: STEP 1 reported −14.9% mean body weight reduction with semaglutide 2.4 mg vs −2.4% on placebo at 68 weeks [1]. SELECT extended the readout to cardiovascular outcomes, showing a 20% relative reduction in 3-point MACE over a mean 39.8 months in semaglutide 2.4 mg recipients without diabetes [4].
Adverse-event profile is dominated by GI signals: nausea 10–46%, vomiting up to 26%, diarrhoea and constipation, largely titration-related [10,11]. The FDA label also carries warnings for pancreatitis (uncommon), cholelithiasis/cholecystitis (elevated), and a boxed warning for thyroid C-cell tumours based on a rodent medullary thyroid carcinoma signal — contraindicated in personal/family history of MTC or MEN-2 syndrome [6].
The glucose-dependent insulinotropic polypeptide (GIP) receptor was historically viewed as obesity-promoting based on rodent knockout data showing protection from diet-induced obesity in GIPR-null mice. Clinical data from dual GIP/GLP-1 agonism — primarily tirzepatide — has substantially complicated that view. Long-acting GIPR agonism in human adipocytes enhances insulin-stimulated fatty-acid uptake and triglyceride storage in the fed state and promotes lipolysis in the fasted state, producing metabolic buffering rather than net fat gain [7,12]. Mechanistic data also show UCP1 and PGC-1α activation consistent with white-fat browning [12].
The clinically relevant addition: tirzepatide 15 mg achieved −20.9% body weight reduction at 72 weeks in SURMOUNT-1 versus the −14.9% reported for semaglutide 2.4 mg in STEP 1, and SURMOUNT-5 head-to-head data confirmed tirzepatide superiority over semaglutide on weight loss [1,13]. Notably, this greater efficacy comes without a proportional increase in GI tolerability burden — translational data show GIPR agonism attenuates GLP-1-induced nausea and emesis via area-postrema circuits [5,14].
GIP also exerts effects on bone metabolism: controlled tissue studies show GIPR activation inhibits osteoclast bone resorption and improves human osteoblast survival [15] — potentially relevant for skeletal preservation during rapid weight loss, though prospective dual-agonist BMD outcome data remain limited.
The glucagon receptor is heavily expressed in the liver, where it drives gluconeogenesis and glycogenolysis. This is the counterregulatory effect that introduces glycaemic risk in any compound carrying glucagon agonism — risk that must be offset by the insulinotropic/glucagonostatic actions of the co-agonised GLP-1 arm [16,18]. The retatrutide Phase 2 T2D readout showed HbA1c reductions of approximately −2% without excess hypoglycaemia, confirming this balance can be engineered through receptor potency ratios [21].
The second hepatic effect is lipid mobilization. The retatrutide MASLD substudy (Phase 2a) reported liver-fat content reductions up to ~82% at 48 weeks by MRI-PDFF, with high rates of non-alcoholic fatty liver disease resolution [18,19]. This is direct evidence that the glucagon arm drives hepatic triglyceride export beyond what weight loss alone would explain.
The third effect is energy expenditure. Glucagon raises resting energy expenditure in humans through hepatic GcgR signalling, most consistently in obese and fasted states [16,17]. A 2025 systematic review of GLP-1/glucagon combination studies confirms this contribution. Pharmacologically, the glucagon arm also produces a dose-dependent resting heart rate increase — retatrutide Phase 2 reported a peak rise of approximately 6.7 bpm at 24 weeks, declining thereafter [19] — and a network meta-analysis ranks retatrutide as producing the largest systolic blood pressure reduction (−7.0 mmHg) among incretin-class agents [20].
Stacking receptor agonism does not simply add effects; it shifts the dominant mechanism. Single GLP-1 agonism is dominated by appetite-driven caloric reduction with secondary glycaemic effect. Adding GIP brings metabolic flexibility and a meaningful weight-loss step-up (~5–6 percentage points in the SURMOUNT-1 vs STEP 1 comparison) without proportional GI tolerability cost. Adding glucagon adds energy expenditure and hepatic lipid mobilization to the appetite-driven loss, with the trade-off of glycaemic management complexity and a heart-rate signal.
| Compound class | Receptor profile | Headline weight-loss readout | Distinct AE signal |
|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 | −14.9% (STEP 1, 68 wk) | GI, gallbladder, MTC boxed warning |
| Tirzepatide 15 mg | GLP-1 + GIP | −20.9% (SURMOUNT-1, 72 wk) | Comparable GI to semaglutide despite greater efficacy |
| Survodutide 4.8 mg | GLP-1 + Gcg | ~19% (Phase 2, 46 wk) | HR rise, hepatic enzyme monitoring |
| Retatrutide 12 mg | GLP-1 + GIP + Gcg | −28.7% (TRIUMPH-4 topline, 68 wk) | HR rise, dysesthesia signal, liver-fat drop |
One of the cleanest framings for adverse-event interpretation in this class is to map each signal back to its likely receptor source.
Two compounds with the same receptor profile can produce different clinical signatures because of differences in receptor potency ratios, signalling bias, half-life, and tissue distribution. Within the GLP-1+GIP space, the published EC50 ratios for tirzepatide are weighted toward GIP relative to GLP-1, which is one hypothesis for the attenuated nausea profile. Within the triagonist space, retatrutide's potency design balances glucagon agonism with sufficient GLP-1/GIP insulin action to keep glycaemic risk manageable [19,21]. This is why drug-by-drug comparisons remain necessary even after the receptor profiles are matched on paper.
Receptor downregulation and signalling adaptation are not uniform across the three receptors. GLP-1R-mediated gastric emptying delay shows clear tachyphylaxis within weeks, while central appetite suppression appears durable across trial windows extending to 68–72 weeks. GIPR effects on adipocyte handling appear sustained in the SURMOUNT-1/-5 windows, though dedicated mechanistic studies of human adipose tissue across multi-year exposure remain limited. GcgR-driven energy expenditure is most consistent in obese and fasted states; durability across multi-year exposure is an active research area.
Energy expenditure is one of the cleanest differentiators between the three receptor classes. Pure GLP-1 agonism does not increase resting energy expenditure meaningfully — weight loss is appetite-driven, and metabolic adaptation (the typical drop in REE with weight loss) still occurs. GIP addition has modest indirect REE effects through adipose tissue browning markers. Glucagon agonism is the only one of the three that directly raises hepatic energy expenditure, which is a major part of why retatrutide produces greater weight loss than would be predicted from appetite suppression alone.
For researchers comparing the current pipeline:
This article documents receptor pharmacology and trial-measured effects of GLP-1, GIP, and glucagon agonism. Remy Peptides supplies research peptides for in-vitro laboratory use only. Nothing on this page is medical advice, dosing guidance, a treatment recommendation, or guidance on personal supplementation or monitoring. Researchers observing effects consistent with the signals described here should consult a qualified clinician; this page does not recommend supplementation, blood-test panels, or self-monitoring protocols.
GLP-1 receptor agonism primarily drives appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion. GIP receptor agonism amplifies glucose-dependent insulin secretion and modulates adipocyte handling of nutrients. Glucagon receptor agonism increases hepatic glucose output and resting energy expenditure, and mobilizes hepatic fat. Each receptor occupies distinct tissue distributions and downstream signaling pathways; trial outcomes track to the combined receptor profile of each compound.
Nausea and vomiting trace primarily to GLP-1 receptor activation in the brainstem area postrema and nucleus of the solitary tract. Reported nausea rates range from 10 to 46 percent with single-agonist GLP-1 drugs during titration, declining with continued dosing. GIP receptor co-agonism appears to attenuate this signal in translational data, which is one hypothesis for why tirzepatide produces comparable nausea rates despite greater weight loss than high-dose semaglutide.
Adding glucagon receptor agonism introduces hepatic glucose output (a counterregulatory effect that must be offset by GLP-1 insulinotropic action), increases resting energy expenditure, mobilizes hepatic triglyceride, and is associated with modest resting heart rate increases. The glucagon arm is what distinguishes triple agonists like retatrutide from GLP-1-only and GLP-1/GIP-only compounds.
GIP receptor agonism in human adipocytes drives metabolic buffering — enhanced insulin-stimulated fatty-acid uptake in the fed state and increased lipolysis in the fasted state. Mechanistic data show UCP1 and PGC-1α activation consistent with white-fat browning. This differs from pure GLP-1 action, which is dominated by appetite-driven caloric reduction. Trial readouts show tirzepatide achieves greater fat-mass loss than semaglutide at comparable lean-mass loss percentages.
Acute gastric-emptying delay from GLP-1 agonism undergoes substantial tachyphylaxis within weeks at the vagal level, while central appetite suppression appears durable. Long-acting agonists show largely normalized gastric emptying by twelve weeks of dosing. GIP receptor effects on adipose handling appear durable across trial windows. Glucagon receptor effects on resting energy expenditure are most consistent in obese and fasted states; long-term receptor signaling dynamics remain an active research area.
Trials measure receptor-attributable effects through specific endpoints: body weight via total body mass and DXA-derived lean/fat partitioning, glycemia via HbA1c and OGTT, hepatic effects via MRI-PDFF for liver fat and liver-function enzymes, cardiovascular signals via continuous and visit-based ECG and ambulatory blood pressure, gallbladder safety via ultrasound, and bone via DXA bone mineral density. Adverse-event capture follows MedDRA standard with attention to GI tolerability, dysesthesia, and injection-site reactions.